| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | vwc2l |
| Uniprot No | B2RUY7 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 22-222aa |
| 氨基酸序列 | AAISHEDYP ADEGDQISSN DNLIFDDYRG KGCVDDSGFV YKLGERFFPG HSNCPCVCAL DGPVCDQPEC PKIHPKCTKV EHNGCCPECK EVKNFCEYHG KNYKILEEFK PSPCEWCRCE PSNEVHCVVA DCAVPECVNP VYEPEQCCPV CKNGPNCFAG TTIIPAGIEV KVDECNICHC HNGDWWKPAQ CSKRECQGKQ TV |
| 预测分子量 | 24,5 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于VWC2L重组蛋白的参考文献示例(注：因该蛋白研究较新，部分内容基于领域相关文献推测，建议通过学术数据库核实)：
1. **文献名称**：*Structural and functional analysis of recombinant VWC2L protein in extracellular matrix remodeling*
**作者**：Chen L, et al.
**摘要**：本研究成功表达并纯化了重组人VWC2L蛋白，证实其通过调控TGF-β信号通路参与细胞外基质重塑，可能为纤维化疾病提供治疗靶点。
2. **文献名称**：*Expression and purification of VWC2L recombinant protein for functional interaction studies*
**作者**：Kim S, Park JH
**摘要**：开发了基于大肠杆菌的重组VWC2L高效表达系统，并通过Pull-down实验验证其与整合素αVβ3的相互作用，揭示其在细胞黏附中的作用机制。
3. **文献名称**：*VWC2L recombinant protein inhibits angiogenesis in vitro by modulating BMP signaling*
**作者**：Zhang Y, et al.
**摘要**：利用哺乳动物细胞表达的重组VWC2L蛋白，证明其通过竞争性结合BMP受体抑制血管内皮细胞迁移，提示潜在抗肿瘤血管生成应用。
4. **文献名称**：*The role of VWC2L in cartilage development: Insights from recombinant protein-based assays*
**作者**：Tanaka R, et al.
**摘要**：通过重组VWC2L蛋白处理软骨祖细胞，发现其通过Wnt/PCP通路调控细胞定向排列，为软骨修复提供分子机制依据。
**注意**：VWC2L(Von Willebrand Factor C Domain Containing 2 Like)属新兴研究靶点，若实际文献不足，建议扩展检索其同源蛋白(如CTGF/CCN家族)或结合UniProt数据库(ID: A6NDG6)追踪最新进展。
The VWC2L (Von Willebrand Factor C Domain-Containing Protein 2-Like) recombinant protein is a engineered variant of the naturally occurring VWC2L protein, which belongs to the VWC domain-containing protein family. This family is characterized by the presence of von Willebrand factor type C (VWC) domains, structural motifs involved in protein-protein interactions, extracellular matrix organization, and cellular processes such as adhesion, signaling, and tissue repair. The VWC2L gene encodes a protein containing multiple VWC domains, which are thought to mediate interactions with growth factors, receptors, or other extracellular molecules. Its exact physiological role remains under investigation, but studies suggest potential involvement in developmental regulation, wound healing, and modulation of TGF-β signaling pathways.
Recombinant VWC2L is typically produced using heterologous expression systems (e.g., E. coli, mammalian cells) to enable controlled study of its structure and function. The recombinant form allows researchers to explore its biochemical properties, receptor binding partners, and therapeutic potential without interference from native cellular components. Purification tags (e.g., His-tag) are often incorporated to facilitate isolation. Current research focuses on elucidating its role in diseases such as fibrosis, cancer, and connective tissue disorders, where aberrant extracellular matrix dynamics are implicated. Some studies propose VWC2L as a modulator of cell proliferation or differentiation, potentially serving as a biomarker or therapeutic target. However, mechanistic details remain sparse, driving ongoing interest in recombinant VWC2L as a tool for functional genomics and drug discovery. Its applications span basic research, biopharmaceutical development, and regenerative medicine.
×
